Canadian Cancer Trials Group Bulletins

2017

Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

19 Oct 2017

General

News: MAC.20 BWEL study story, Northeast Cancer Centre
Northeast Cancer Centre in Sudbury takes part in breast cancer study BWEL

Read more ....

'

Trial Management Group

Citation: SC.23,dexamethasone lowers the rate of pain flare
Citation for SC23 secondary analysis: Dexamethasone lowers the rate of pain flare in cancer patients with bone metastases undergoing radiation therapy

Read more ....

'

Closed to Accrual: MA.32D (Alliance A211201?)
Change In Mammographic Density with Metformin Use: A Companion Study to NCIC CTG Study MA.32

Read more ....

'

Central Activation: MAC.22 TMIST Trial
MAC.22 Tomosynthesis Mammographic Imaging Screening Trial (TMIST), has been centrally activated.

Read more ....

'

Central Activation: PM.1 CAPTUR
PM.1 Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)has been centrally activated.

Read more ....

'

Central Activation: MAC.21 (Alliance A011502)
CCTG Trial MAC.21 (Alliance A011502): A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial has been centrally activated.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

04 Oct 2017

General

New pancreatic cancer trial provides hope to BC family
CCTG led PA.7 combines immunotherapy drugs with standard chemotherapy An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer - the deadliest cancer facing Canadians today.

Read more ....

'

Holiday Closure CCTG Operations and Statistics Office
Canadian Thanksgiving Holiday closure at the CCTG main office in Kingston on Monday, October 9.

Read more ....

'

Trial Management Group

CCTG MAC.20 Randomized Phase III Trial open to accrual
We are please to announce that the MAC.20 trial is open to Canadian registrations and randomizations.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

20 Sep 2017

General

In the News: Dr. Wendy Parulekar interview
A feature story in the latest edition of Queen's Research publication e-Affects on CCTG's Dr. Wendy Parulekar - Making a Difference through Clinical

Read more ....

'

Congrats to the Trialblazers Mudmoiselle 2017 Team
The CCTG Trialblazers ran and sludged their way trough the mud in support of the the Canadian Cancer Society last weekend.

Read more ....

'

Trial Management Group

Citations: MAC4 and MAC5 publications
There are two citations for the CCTG's studies MAC4 and MAC5 publications

Read more ....

'

Closed to Accrual: CCTG IND.226
The CCTG IND.226 study has been closed to accrual. A phase Ib study of durvalumab (MEDI4736) with or without tremelimumab in patients with advanced incurable solid malignancies

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

06 Sep 2017

General

CCTG Trial Blazers at Mudmoiselle 2017
The CCTG Trailblazers will be participating in the Kingston Mudmoiselle on September 16th to support the Canadian Cancer Society. This intrepid team will run 5km through a mud obstacle course and get filthy for a good cause!

Read more ....

'

In the news: CCTG featured in BIG newsletter
The latest issue of BIG Research in Focus is now available.CCTG?s MA.39 breast cancer clinical trial receives green light from funding bodies is on page 14.

Read more ....

'

CCTG is hiring a SENIOR INVESTIGATOR
CCTG is currently looking for a Physician with oncology training to be the SENIOR INVESTIGATOR for our Investigational New Drug Program.

Read more ....

'

Citations: MA.31 and CEC1
Citations for MA31 and CEC1 trials

Read more ....

'

Trial Management Group

NCTN new Registration and Credential Repository
The National Clinical Trials Network (NCTN) launched a new Registration and Credential Repository (RCR) system. RCR is a self-service online person registration application with electronic signature and document submission capability.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

23 Aug 2017

General

ASCO Young Investigator Award
Applications are now open for @ConquerCancerFd Young Investigator Awards - apply now!

Read more ....

'

Precision Oncology takes a step forward at CCTG
Infrastructure funding awarded for slide scanner from Canadian Foundation for Innovation through the John R. Evans Leaders Fund (JELF)for a digital histology slide scanner.

Read more ....

'

Dr. Scott Berry retires from the DSMC
Sincere gratitude to Dr. Scott Berry, medical oncologist at the Sunnybrook Odette Cancer Centre and Associate Professor at the University of Toronto, for his commitment and dedication to CCTG.

Read more ....

'

Another successful New Investigators Course at CCTG
Developed by the Canadian Cancer Trials Group (CCTG), the course is unique in Canada, aimed at fellows and junior faculty interest in cancer clinical research in the fields of medical, radiation, and surgical oncology.

Read more ....

'

Trial Management Group

Notification of CCTG Policy Updates
There have been recent policy updates at CCTG. These included changes to processes for site team protocol training and completion of delegation logs, as well as various other tips and reminders for CCTG trials.

Read more ....

'

Trail CCTG MEC.5: Step 1 closed to accrual
The MEC.5 trial (SWOG S1404) has met its accrual target and is officially closed to new patient registration to STEP 1.

Read more ....

'

Trial CO.28 Central Activation
CCTG-led trial NEOADJUVANT CHEMOTHERAPY, EXCISION AND OBSERVATION FOR EARLY RECTAL CANCER: The NEO Trial. CCTG Trial CO.28 has been centrally activated.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

09 Aug 2017

General

National Clinical Trials Network (NCTN) launches new systems
The National Clinical Trials Network (NCTN) of the US NCI is planning to launch a new Registration and Credential Repository (RCR) system and a Delegation of Tasks Log (DTL) in the coming months.

Read more ....

'

CCTG Trialblazers raising money for Mudmoiselle 2017
The CCTG Trialblazers be participating in the Kingston Mudmoiselle on September 16th to support the Canadian Cancer Society. Show your support for their muddy work!

Read more ....

'

Publication: ALC.2 in the NEJM
Recently published in the New England Journal of Medicine - Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Read more ....

'

News: CCTG MA.17R trial featured in BIG annual report
CCTG MA.17R trial featured as one of the highest impact studies in the world in the Breast International Group (BIG) annual report.

Read more ....

'

Trial Management Group

Trial Closure: LY7 (EORTC) Phase III Randomized Trial
Chimeric Anti-CD20 Monoclonal Antibody (Rituximab)in Remission Induction and Maintenance Treatment of Relapsed Follicular Non-Hodgkins Lymphoma: A Phase III Randomized Clinical Trial has been permanently closed by the lead group.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

26 Jul 2017

General

News: Story on BWEL study (Alliance: A011401) (CCTG: MAC.20)
Article discussing weight loss program that aims to pinpoint the role of obesity in breast cancer.

Read more ....

'

CCTG job openings
We are looking for a few good people to join us in Kingston at the central operations and statistics office.

Read more ....

'

CIHR Celebrating Health Research
CIHR wants to hear from you: Tell them about your research in 150 words.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

12 Jul 2017

General

The Conversation launches in Canada
The Conversation is an international platform for news written by researchers. A new and exciting tool for both faculty and students to promote their scholarship.

Read more ....

'

News: Advanced radiotherapy improves lung cancer survival
CCTG study BR.28 - international partnership highlighted in University of Manchester article

Read more ....

'

Report: How to Optimize the Canadian Academic System
The Canadian Academy of Health Sciences convened an expert panel to examine how research institutions evaluate and recognize the contributions of individuals for work done within research teams, and to identify promising practices to improve such evaluation and recognition.

Read more ....

'

Trial Management Group

Trial Milestone: CO.26 has reached target accrual
The CO.26 colorectal cancer trial has met its target accrual of 180 patients.

Read more ....

'

Trial Milestone: CX.5(SHAPE)
Cervical Cancer CX.5(SHAPE) trial hits 17 accruals in June alone!

Read more ....

'

CCTG CEC.5 (Alliance A221208) | Opportunity still exists for additional sites in Canada
Radionecrosis is growing problem as patients live longer after repeated treatments with high dose radiation, including radiosurgery. Patient participation in this trial is needed.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

29 Jun 2017

General

Study Story: CO.21 Strengthening the body
Clinical trials don't always set out to prove whether drugs are effective. They can also test surgeries, radiation therapy, or even exercise.

Read more ....

'

Recent Citations
Citations for CCTG trials BR.28 and MA.32

Read more ....

'

1 in 2 Canadians will get cancer, 1 in 4 will die of disease
According to Canadian Cancer Statistics 2017 released last week by the Canadian Cancer Society in partnership with the Public Health Agency of Canada and Statistics Canada.

Read more ....

'

Accrual Utility Support Materials
Additional resources to assist member sites in the use of the new Accrual Utility have been posted on the Utility page.

Read more ....

'

Central office holiday closure
CCTG's central office will be closed Monday, July 3, 2017 for the Canada Day holiday weekend.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

14 Jun 2017

Disease Site Updates

Hematology Disease Site Committee Executive needs you!
CCTG is looking for member site Clinical Research Associates(CRA) to sit on the Hematology Disease Site Committee Executive.

Read more ....

'

EDC - Rave

Importance Notice: Medidata Rave maintenance
There will be planned maintenance to the Medidata Rave (EDC) System starting on Jun 17, 2017 6:00 AM EDT and ending on Jun 17, 2017 12:00 PM EDT

Read more ....

'

General

Recent citations
Citations for the CCTG led randomized phase 3 study LY.12

Read more ....

'

News story on a study looking at pregnancy for breast cancer patients
Recent press coverage detailed the results of an international study around pregnancy and breast cancer. It highlighted a new study that CCTG will be participating in and we are still enrolling patients.

Read more ....

'

Single-Study Centres and DSMC Summary Reports are now available.
Trial-specific DSMC Summary Reports are now posted on the trial websites for download and submission.

Read more ....

'

ASCO 2017 and CCTG was there!
We had a number of members presenting abstracts and posters at this years event.

Read more ....

'

Office of Compliance and Oversight

Changes to the Informed Consent Forms
Please be aware of the changes that have been made to the Informed Consent Forms (ICFs) posted on the trial web pages.

Read more ....

'

Opportunities to join the CCTG team!
CCTG is growing again and we are looking for a Monitor/Auditor at our central offices located in Kingston, Ontario.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

13 Jun 2017

Disease Site Updates

Hematology Disease Site Committee Executive needs you!
CCTG is looking for member site Clinical Research Associates(CRA) to sit on the Hematology Disease Site Committee Executive.

Read more ....

'

EDC - Rave

Importance Notice: Medidata Rave maintenance
There will be planned maintenance to the Medidata Rave (EDC) System starting on Jun 17, 2017 6:00 AM EDT and ending on Jun 17, 2017 12:00 PM EDT

Read more ....

'

General

Recent citations
Citations for the CCTG led randomized phase 3 study LY.12

Read more ....

'

News story on a study looking at pregnancy for breast cancer patients
Recent press coverage detailed the results of an international study around pregnancy and breast cancer. It highlighted a new study that CCTG will be participating in and we are still enrolling patients.

Read more ....

'

Single-Study Centres and DSMC Summary Reports are now available.
Trial-specific DSMC Summary Reports are now posted on the trial websites for download and submission.

Read more ....

'

ASCO 2017 and CCTG was there!
We had a number of members presenting abstracts and posters at this years event.

Read more ....

'

Office of Compliance and Oversight

Changes to the Informed Consent Forms
Please be aware of the changes that have been made to the Informed Consent Forms (ICFs) posted on the trial web pages.

Read more ....

'

Opportunities to join the CCTG team!
CCTG is growing again and we are looking for a Monitor/Auditor at our central offices located in Kingston, Ontario.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

31 May 2017

General

CCTG Accrual Utility is live online
We are excited to announce that the CCTG Accrual Utility is now available to all CCTG members. This utility is a web-based application that provides real-time accrual information.

Read more ....

'

7 Days in May crew arrives at CCTG!
7 Days in May is a bike ride around Lake Ontario that has grown to be a major fundraiser for pancreatic cancer clinical trial research.

Read more ....

'

CCTG at ASCO 2017 - Chicago, Illinois June 2-6, 2017
American Society of Clinical Oncology Annual Meeting Presentations and awards list for CCTG members is now available online.

Read more ....

'

Group Administrators Office

The NEW DEADLINE for receiving a CME certificate is June 5.
Please be aware that we have extended the deadline for participants wanting to claim credits. To claim a credit participants must use the CME Evaluation Program available on the 2017 Spring Meeting website.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

18 May 2017

Group Administrators Office

ESMO clinical benefits scale
It has been 2 years since the publication of the ESMO clinical benefits scale. Please consider talking a short survey to assist in determining how the scale is being used in different countries.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

17 May 2017

General

Clinical Trials Day May 19 2017
The Association of Clinical Research Professionals each Clinical Trials Day helps raise clinical trial awareness and honors clinical research professionals by recognizing their contributions to public health and medical progress.

Read more ....

'

The Canadian Cancer Society's Research Impact Report
The Canadian Cancer Society's Research Impact Report has recently been published and features CCTG.

Read more ....

'

Trial Citations
There have been citations for MA 31 and IND 198 trials that have recently been published online.

Read more ....

'

Supporting the 7 Days in May Riders!
Every year the 7 Days in May riders raise awareness and money for Pancreas Cancer research

Read more ....

'

Ottawa Hospital recognizes team awards
Two study groups from The Ottawa Hospital received the Investigation New Drug Program Team Award from the Canadian Cancer Trials Group. Recently Ottawa Hospital recognized their teams achievements.

Read more ....

'

Group Administrators Office

DEADLINE for receiving a CME certificate is 19 May 2017
Participants wanting to claim credits must use our CME Evaluation Program available on the 2017 Spring Meeting website.

Read more ....

'

Trial Management Group

New Phase III Study Coordinators at CCTG
CCTG is pleased to welcome two new Phase III Study Coordinators to our team and continue to recruit Study Coordinators for the Group.

Read more ....

'

IND.219 trial closed to accrual
IND.219, A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-Based Chemotherapy is closed to accrual.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

03 May 2017

General

JAMA Oncology Publication: SC.23 trial
Effect of Radiotherapy on Painful Bone Metastases, a Secondary Analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23 published in JAMA Oncology February 9, 2017.

Read more ....

'

Canadian Cancer Trials Group awarded $23.5M over 5 years
The Canadian Cancer Society (CCS) has renewed its commitment to the Canadian Cancer Trials Group (CCTG) through a major funding award of $23.5 million over 5 years.

Read more ....

'

Group Administrators Office

CCTG 2017 Annual Spring Meeting Follow-up
CCTG 2017 Annual Spring Meeting - Travel Reimbursement and CME Certificate - Information and Deadlines

Read more ....

'

Trial Management Group

Trial Activation: CO.27
CO.27 (IROCAS), A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-Risk Stage III Colon Cancer in Adjuvant Setting, has been centrally activated.

Read more ....

'

Closed to accrual: IND.229
IND.229 was closed to further accrual on April 20, 2017. The accrual target of 15 patients was reached within 8 months of central activation. All patients are now off protocol treatment with follow-up of patients to continue according to the protocol.

Read more ....

'

Closed to accrual IND.221
IND.221 was closed to further accrual on April 20, 2017. Accrual to Part 1 (18 patients) and Part 2, Stage 1 (41 patients) was completed.

Read more ....

'

Trials permanently closed: MA17R and MA20
MA17R and MA20 trials were permanently closed on Wednesday April 19th. Participating sites were directly notified.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

19 Apr 2017

General

Spring Meeting 2017: Plenary Presentation
Genitourinary Disease Site Committee has organized a Plenary Presentation during the Spring Meeting at the end of this month. Novel Approaches to the Treatment of Urothelial Carcinoma.

Read more ....

'

Spring Meeting 2017 is nearly here!
The Canadian Cancer Trials Group 2017 Annual Spring Meeting is next week, make sure you have the most up-to-date information.

Read more ....

'

In Memoriam - Dr. Suzanne Richter
It is with great sadness that we share the passing of Dr. Suzanne Richter who died suddenly on Saturday, April 1.

Read more ....

'

Spring Meeting 2017: Canadian Cancer Trials Group Awards
Introducing the winners: Each year, at the CCTG Annual Spring Meeting of Participants, we recognize individuals and groups who have made significant contributions to cancer clinical trials research.

Read more ....

'

Group Administrators Office

Job opening at CCTG Central Office
Canadian Cancer Trials Group (CCTG) is currently looking to fill the position of Manager, Office of Compliance and Oversight (OCO).

Read more ....

'

Office of the Director

CCTG Trailblazers Supporting Relay for Life
The Canadian Cancer Trials Group Central Office Trialblazers, are now training for the Relay for Life Event in Kingston on June 3, 2017. Find out how you can support us!

Read more ....

'

Trial Management Group

BLC.4 Trial Activation
CCTG BLC.4/SWOG 1605 study a Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Read more ....

'

BL12 Closed to Accrual
The CCTG led BL12 study, has met its target accrual in both Canada and Australia.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

05 Apr 2017

General

The Tragically Hip recognized at CCTG
The Canadian Cancer Society (CCS) recognized Kingston hometown heroes the Tragically Hip for their support of brain cancer research at CCTG in Kingston.

Read more ....

'

Spring Meeting 2017
The date is fast approaching for the 2017 Spring Meeting. Make sure you are registered to attend and have your travel arrangements in place.

Read more ....

'

CCTG has new career opportunities!
The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has current career opportunities available.

Read more ....

'

Trial Management Group

New CCTG Study Coordinators at CCTG
We are pleased to welcome two new members to the trial management team.

Read more ....

'

Trial closure: PR17
PR17 randomised Phase III Trial of Enzalutamide in First Line Androgen Deprivation Therapy is closed to randomization.

Read more ....

'

Trial closure: IND 218
IND.218 (A Study of Vinblastine and Temsirolimus in Pediatric Patients with Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours)is closed to further accrual.

Read more ....

'

Trial activation: ALC.4
ALC.4 (E1910) study, A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

22 Mar 2017

General

CE.6 Trial Published in New England Journal of Medicine
Canadian Cancer Trials Group CE.6 Clinical Trial published in the New England Journal of Medicine Study finds that adding temozolomide chemotherapy to short-course radiation therapy improves overall survival for older patients.

Read more ....

'

Group Administrators Office

The New Investigator Clinical Trials Course
This course is an important component of the CCTG mandate to provide investigator education and training. The major goal of this three-day course is to familiarize new investigators from across the country with the essentials of clinical trial conduct.

Read more ....

'

CCTG 2017 Annual Spring Meeting
The draft Overall Schedule is posted on the Spring Meeting website, click "Overall Schedule." Please check the schedule often as meeting times may change and new meetings may be added.

Read more ....

'

Trial Management Group

CCTG BRC.5 closed to new patient registration
The BRC.5 trial (CALGB 140503) has met its accrual target and was officially closed to new patient registration.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

08 Mar 2017

General

Targeted Anti-Cancer Therapies Congress (TAT) 2017
TAT 2017 is underway with CCTG's Dr.Lesley Seymour, Director, Investigational New Drug Program chairing some of the sessions.

Read more ....

'

Bulletin survey closes soon
This is your last chance to tell us what you think by filling out this short bulletin survey.

Read more ....

'

The Lancet Oncology publishes iRECIST
RECIST working group issues modified guideline for immunotherapy in a recent publication in The Lancet Oncology

Read more ....

'

Group Administrators Office

The Canadian Cancer Trials Group 2017 Annual Spring Meeting
The Canadian Cancer Trials Group 2017 Annual Spring Meeting of Participants will be held April 28 - 30, 2017 at the Chelsea Hotel in Toronto. Make sure that you have all the up to date information you need to join us at this year's meeting.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

22 Feb 2017

General

Target Insight 2017 Conference May 1
This year's theme is Personalized Radiation Medicine: From Theory to Practice The conference will be held on May 1 right after the CCTG spring meeting - if you are already coming to the Spring Meeting extend your stay to attend!

Read more ....

'

CCTG Bulletin Survey
Did you know that we are coming up on the 10th anniversary of the CCTG bulletin? Let us know how you think we can improve the bulletin by filling out this short survey.

Read more ....

'

Group Administrators Office

The Canadian Cancer Trials Group 2017 Annual Spring Meeting
The funded and non-funded invitations for this year's meeting have been sent and the nomination deadline is fast approaching.

Read more ....

'

Trial Management Group

Recent Publication
RECIST (ONLINE) citation

Read more ....

'

Trial Activation
BR.34: A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab +/- Platinum Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC) has been centrally activated. Open to all member centres.

Read more ....

'

Trial Closure
The HN6 trial has now been deemed permanently closed.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

10 Feb 2017

General

Media Release: Effect of Radiotherapy on Painful Bone Metastases
To reduce pain and improve quality of life, radiation treatment should be offered to patients with cancer that has spread to the bone (bone metastases), even those with poor expected survival, according to a study published yesterday in JAMA Oncology.

Read more ....

'

Update: Correction MA.37 activation announcement
Please note that Canadian participation in MA.37 is limited to 20 pre-selected and approved sites. If your site is not on the approved list, please contact the MA.37 CCTG study team for more information. cdavidson@ctg.queensu.ca

Read more ....

'

The 2017 CCTG Annual Spring Meeting
It is that time of year again to get ready for Spring - the CCTG Spring meeting information is ready!

Read more ....

'

CCTG Bulletin is changing delivery dates to Wednesday
The bi-weekly CCTG bulletin will now be sent to you on Wednesdays. The next edition will arrive on February 22 and will include a survey for you to fill out. It is your turn to tell us what you think about the bulletin and how we can improve!

Read more ....

'

Trial Management Group

Trial Activated: IND.223
CCTG-led trial IND.223, A Phase II Study of Palbociclib, a CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer, is now centrally activated.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

27 Jan 2017

General

Recent Publication
There was one recent publication reporting results of a sub-group analysis from CCTG LY.12.

Read more ....

'

CCTG Supporting World Cancer Day!
World Cancer Day is a worldwide event that takes place every year on 4 February and unites the world's population in the fight against cancer.

Read more ....

'

Group Administrators Office

2017 CCTG Recognition Awards
The Central Operations and Statistics Office is seeking nominations for the 2017 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group.

Read more ....

'

Trial Management Group

Trial Activations
Two trials were recently activated -- MA.37 (14-03) and OVC.2 (NRG-GY0005).

Read more ....

'

Trial Closed to Accrual
IND.216 - A Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia - has been closed to accrual.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Special Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Special Bulletin

18 Jan 2017

Group Administrators Office

Queen's University Systems Update for Jan 18-19 2017
Queens University, our host institution is undertaking urgent power supply and systems upgrades in the next 24 hours.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

13 Jan 2017

General

Single-Study Centres and DSMC Summary Reports
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.

Read more ....

'

Recent Publications
There were a number of recent publications, including the primary results of HN.6 and an associated quality of life analysis.

Read more ....

'

CCTG receives $8.7 million from CFI
Earlier this week, CCTG received a five-year, $8.68 million grant from the Canada Foundation for Innovation (CFI). This funding will support CCTG's Operations and Statistics Centre at Queen's University in Kingston.

Read more ....

'

Office of the Director

CCTG Recruiting Senior Investigator
CCTG Operations and Statistics Centre based at Queen's University Cancer Research Institute in Kingston, Ontario is seeking a Physician trained in a cancer-related specialty as a Senior Investigator.

Read more ....

'

Trial Management Group

Trial Activations
Three trials were recently centrally activated -- CEC.5 (Alliance A221208), OVC.1 (NRG-GY0004), and GA.3 (AGITG-AG0315OG).

Read more ....

'

Trial Closed to Accrual
PR.13 (MRC PR10) - RADICALS: Radiotherapy and Androgen Deprivation In Combination After Local Surgery - was closed to accrual on December 30, 2016 after reaching its accrual target of 4000 patients.

Read more ....

'

Permanent Trial Closure
BRC.1 (RTOG 0214) - A Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer trial - has been permanently closed.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletins